Literature DB >> 18476097

Investigations by cell-mediated immunologic tests and therapeutic trials with thymopentin in vaginal mycoses.

W Mendling1, U Koldovsky.   

Abstract

OBJECTIVE: According to unsatisfactory therapeutic results in patients with chronically recurrent vaginal candidosis, we investigated if immunologic patient factors could be found and treated.
METHODS: In 42 women with chronically recurrent and 20 women with acute Candida albicans vulvovaginitis, as well as 14 women with C. glabrata vaginitis, the following investigations were carried out: identification of yeast species; quantification of T lymphocytes and their subpopulations in sera; proliferation tests of T lymphocytes in vitro; treatment of 18 patients with chronically recurrent vaginal candidosis with the synthetic T-lymphocyte- stimulator thymopentin; and, finally, control of the above-mentioned parameters in the clinical course.
RESULTS: Women with C. albicans vulvovaginitis showed fewer T lymphocytes and subpopulations in the peripheral blood than healthy women. Only the number of non-specific killer (NK) cells, however, was significantly lower in cases of acute C. albicans vulvovaginitis. In women with C. glabrata vaginitis, the number of T lymphocytes in the blood was within the normal range. In vitro proliferation tests using mitogens, bacterial antigens, and commercially available candida antigens with and without addition of thymopentin were carried out on the T lymphocytes of women with chronically recurrent C. albicans vulvovaginitis. These tests revealed no significant differences compared with the other patients with C. albicans infections. The patients were treated with thymopentin. Those women who revealed an increase of initially low numbers of T-helper cells recovered from vaginal candidosis after thymopentin treatment.
CONCLUSIONS: The peripheral T lymphocytes may be diminished in patients with chronically recurrent C. albicans vaginitis, and immunologic treatment can reduce the relapse rate.

Entities:  

Year:  1996        PMID: 18476097      PMCID: PMC2364501          DOI: 10.1155/S1064744996000439

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  22 in total

Review 1.  Host defense system interactions with Candida.

Authors:  R A Greenfield
Journal:  J Med Vet Mycol       Date:  1992

2.  Studies on the role of macrophages in experimental candidosis in mice.

Authors:  B K Sinha; D P Monga; S Prasad
Journal:  Mykosen       Date:  1987-03

3.  Carriage of oral Candida albicans associated with a high number of circulating suppressor T lymphocytes.

Authors:  M Melbye; H Schønheyder; L Kestens; A Stenderup; P L Gigase; P Ebbesen; R J Biggar
Journal:  J Infect Dis       Date:  1985-12       Impact factor: 5.226

4.  [Significance of phagocytes and the T lymphocyte system in the defense against Candida albicans infections (review)].

Authors:  I Török; B Farkas
Journal:  Mykosen       Date:  1986-10

5.  Differences in the intracellular killing of proteinase-positive and proteinase-negative Candida albicans strains by granulocytes.

Authors:  T Walther; M Rytter; C Schönborn; U F Haustein
Journal:  Mykosen       Date:  1986-04

6.  Immunological findings in patients with chronically recurrent vaginal candidosis and new therapeutic approaches.

Authors:  W Mendling; U Koldovsky
Journal:  Mycoses       Date:  1989-08       Impact factor: 4.377

7.  Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents.

Authors:  V Redondo-Lopez; M Lynch; C Schmitt; R Cook; J D Sobel
Journal:  Obstet Gynecol       Date:  1990-10       Impact factor: 7.661

Review 8.  Pathogenicity determinants of Candida.

Authors:  M A Ghannoum; K H Abu-Elteen
Journal:  Mycoses       Date:  1990-06       Impact factor: 4.377

9.  Rapid killing of monocytes in vitro by Candida albicans yeast cells.

Authors:  D L Danley; J Polakoff
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

10.  A macrophage defect in women with recurrent Candida vaginitis and its reversal in vitro by prostaglandin inhibitors.

Authors:  S S Witkin; J Hirsch; W J Ledger
Journal:  Am J Obstet Gynecol       Date:  1986-10       Impact factor: 8.661

View more
  14 in total

1.  Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis.

Authors:  F L Wormley; J Chaiban; P L Fidel
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).

Authors:  W Mendling; K Friese; I Mylonas; E-R Weissenbacher; J Brasch; M Schaller; P Mayser; I Effendy; G Ginter-Hanselmayer; H Hof; O Cornely; M Ruhnke
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

Review 3.  Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins.

Authors:  Junko Yano; Mairi C Noverr; Paul L Fidel
Journal:  Cytokine       Date:  2011-12-17       Impact factor: 3.861

4.  Prospects for development of a vaccine to prevent and control vaginal candidiasis.

Authors:  Paul L Fidel; Jim E Cutler
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

Review 5.  Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: "Neutrophil Anergy".

Authors:  Junko Yano; Brian M Peters; Mairi C Noverr; Paul L Fidel
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

6.  Transcriptomic analysis of vulvovaginal candidiasis identifies a role for the NLRP3 inflammasome.

Authors:  Vincent M Bruno; Amol C Shetty; Junko Yano; Paul L Fidel; Mairi C Noverr; Brian M Peters
Journal:  MBio       Date:  2015-04-21       Impact factor: 7.867

7.  Vaginal Heparan Sulfate Linked to Neutrophil Dysfunction in the Acute Inflammatory Response Associated with Experimental Vulvovaginal Candidiasis.

Authors:  Junko Yano; Mairi C Noverr; Paul L Fidel
Journal:  mBio       Date:  2017-03-14       Impact factor: 7.867

8.  Design and Development of a Novel Peptide for Treating Intestinal Inflammation.

Authors:  Lulu Zhang; Xubiao Wei; Rijun Zhang; Jim N Petitte; Dayong Si; Zhongxuan Li; Junhao Cheng; Mengsi Du
Journal:  Front Immunol       Date:  2019-08-06       Impact factor: 7.561

Review 9.  Immunopathology of Recurrent Vulvovaginal Infections: New Aspects and Research Directions.

Authors:  Namarta Kalia; Jatinder Singh; Manpreet Kaur
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

Review 10.  Candida vaginitis: when opportunism knocks, the host responds.

Authors:  Brian M Peters; Junko Yano; Mairi C Noverr; Paul L Fidel
Journal:  PLoS Pathog       Date:  2014-04-03       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.